Microplastics and Nanomaterials: Understanding Emerging Contaminants in Environmental Testing

<p><strong>🎤Matthew Bolino</strong></p><p><strong>How do the hidden carbohydrate structures on your favorite protein powders shape the gut microbiome? &nbsp;In this episode of Concentrating on Chromatography, Matthew Bolino, M.S., from the University of Nevada, Reno, breaks down his latest research on N‑glycans from common dietary proteins (whey, egg white, soy, and pea) and how their structural diversity influences microbial fermentation and short‑chain fatty acid production.</strong></p><p>Bolino explains what N‑glycans are, why they behave like fiber in the gut, and how his team isolates and characterizes them using ethanol washes, enzymatic release (PNGase F and gut‑derived endoglycosidases), and advanced MALDI‑TOF and HILIC‑QTOF workflows. &nbsp;He also discusses his 2025 work comparing synthetic versus bovine whey N‑glycomes and mapping N‑glycan profiles across dietary protein sources, revealing how glycan architecture can reshape community diversity in in vitro fecal fermentations.</p><p>Geared toward undergraduate and early‑career analytical chemists, this conversation dives into practical mass spec trade‑offs (<strong>MALDI vs QTOF vs LC/GC</strong>), real‑world troubleshooting in glycomics labs, and how microbiome‑targeted therapeutics and “symbiotic” designs may emerge from pairing specific microbes with preferred glycan structures. &nbsp;Bolino closes with career advice on building biomolecular analysis skills, understanding instrumentation fundamentals, and entering the rapidly growing field of glycomics and microbiome research.</p><h3><strong>Video Transcription</strong></h3><h4><span><strong>Introduction</strong></span></h4><p>Glycomics has emerged as a rapidly developing field within biomolecular science, expanding our understanding of post-translational modifications beyond well-known processes such as phosphorylation. Among these modifications, <strong>protein glycosylation</strong>—the covalent attachment of carbohydrate structures to proteins—plays a critical role in biological function, molecular recognition, and cellular communication.</p><p>This discussion focuses on <strong>N-glycans</strong>, a class of structurally complex carbohydrates linked to proteins, and their occurrence in common dietary protein sources such as whey, egg white, soy, and pea protein. Particular emphasis is placed on their structural diversity, analytical workflows, and emerging relevance in gut microbiome research.</p><h4><span><strong>Fundamentals of N-Glycans</strong></span></h4><p>N-glycans are oligosaccharide structures covalently attached to proteins via nitrogen atoms, typically at asparagine residues. They represent one of the two major classes of protein glycosylation, alongside O-glycans.</p><p>These glycans are characterized by:</p><ul><li><strong>High structural diversity</strong>, arising from variations in monosaccharide composition and linkage patterns</li><li><strong>Large size</strong>, typically comprising 7–15 monosaccharide units</li><li><strong>Complex branching architectures</strong>, leading to a vast number of possible configurations</li></ul><p>Common monosaccharide components include:</p><ul><li>Mannose</li><li>Galactose</li><li>N-acetylglucosamine</li><li>N-acetylgalactosamine</li><li>Sialic acids</li></ul><p>Unlike free carbohydrates present in foods (e.g., glucose, lactose), N-glycans are <strong>protein-bound</strong>, which significantly influences their biological behavior.</p><h4><span><strong>Biological Function and Dietary Relevance</strong></span></h4><p>N-glycans play multiple roles in biological systems, including:</p><ul><li>Modulation of <strong>protein stability</strong></li><li>Regulation of <strong>protein trafficking and localization</strong></li><li>Facilitation of <strong>cell–cell communication and immune recognition</strong></li></ul><p>They are particularly abundant on <strong>membrane and surface proteins</strong>, where they contribute to molecular signaling processes.</p><p>From a dietary perspective, N-glycans exhibit unique behavior. Due to their size and protein-bound nature, they are not readily digested in the upper gastrointestinal tract. Instead, they can reach the colon, where they may function analogously to <strong>dietary fiber</strong>, interacting with the gut microbiota.</p><h4><span><strong>Research Motivation</strong></span></h4><p>The investigation of N-glycans in dietary proteins was initially driven by interest in protein nutrition and supplementation, particularly in the context of muscle growth and protein quality. However, this focus expanded upon recognition of the importance of glycosylation in biological systems.</p><p>The field of glycomics offers:</p><ul><li>Extensive <strong>structural variability</strong>, enabling diverse biological functions</li><li>Relevance in <strong>disease mechanisms</strong>, including cancer, where glycosylation patterns can influence immune evasion</li><li>Opportunities to explore <strong>diet–microbiome interactions</strong></li></ul><p>This combination of nutritional, biochemical, and biomedical relevance makes N-glycan research particularly compelling.</p><h4><span><strong>Experimental Workflow for N-Glycan Analysis</strong></span></h4><p>The analysis of N-glycans requires a multi-step workflow due to their covalent attachment to proteins.</p><h5><span><strong>1. Protein Purification</strong></span></h5><p>Dietary protein samples often contain:</p><ul><li>Free sugars</li><li>Lipids</li><li>Other matrix components</li></ul><p>To isolate glycoproteins:</p><ul><li><strong>Cold ethanol precipitation</strong> is used to remove free carbohydrates</li><li>Multiple washing steps ensure removal of residual sugars</li><li>A <strong>phenol–sulfuric acid assay</strong> is applied to confirm the absence of free sugars</li></ul><h5><span><strong>2. Enzymatic Release of N-Glycans</strong></span></h5><p>N-glycans are enzymatically cleaved from proteins using:</p><ul><li><strong>PNGase F (Peptide-N-Glycosidase F)</strong></li></ul><p>This enzyme:</p><ul><li>Specifically cleaves the glycan from the protein backbone</li><li>Preserves the intact glycan structure</li></ul><p>Alternative approaches using <strong>gut-derived enzymes</strong> are being explored to improve accessibility and yield.</p><h5><span><strong>3. Glycan Purification and Labeling</strong></span></h5><p>Following release:</p><ul><li>Glycans are purified from the protein matrix</li><li>Chemical labeling is performed (e.g., 2-AA or procainamide tagging)</li></ul><p>Labeling enhances:</p><ul><li>Detection sensitivity</li><li>Chromatographic behavior</li></ul><h5><span><strong>4. Analytical Techniques</strong></span></h5><p>Two primary analytical platforms are employed:</p><ul><li><strong>MALDI-TOF MS</strong><ul><li>High sensitivity</li><li>Broad structural coverage</li></ul></li><li><strong>HILIC-LC-MS</strong><ul><li>Improved reproducibility</li><li>Enhanced chromatographic separation</li></ul></li></ul><p>These approaches provide <strong>semi-quantitative data</strong>, where signal intensity reflects relative abundance rather than absolute concentration.</p><h4><span><strong>Analytical Challenges</strong></span></h4><p>Several challenges are associated with N-glycan analysis:</p><h5><span><strong>Low Abundance</strong></span></h5><ul><li>Dietary proteins typically contain only <strong>1–2% glycan content by weight</strong></li><li>This limits yield and complicates downstream applications</li></ul><h5><span><strong>Sample Preparation Complexity</strong></span></h5><ul><li>Extensive purification is required to eliminate free sugars</li><li>Contamination risks must be carefully managed</li></ul><h5><span><strong>Instrumentation Trade-Offs</strong></span></h5><ul><li>Different analytical platforms offer complementary advantages</li><li>No single technique provides complete structural and quantitative information</li></ul><h4><span><strong>Differences Between Plant and Animal N-Glycans</strong></span></h4><p>Comparative analysis reveals distinct differences in glycan composition:</p><h5><span><strong>Plant-Derived Proteins (e.g., soy, pea)</strong></span></h5><ul><li>Predominantly <strong>high-mannose structures</strong></li><li>Lower monosaccharide diversity</li><li>Simpler glycan architectures</li></ul><h5><span><strong>Animal-Derived Proteins (e.g., whey, egg white)</strong></span></h5><ul><li>Greater <strong>structural complexity</strong></li><li>Inclusion of diverse monosaccharides (e.g., sialic acids)</li><li>More elaborate branching patterns</li></ul><p>These differences have important implications for biological function and microbial interactions.</p><h4><span><strong>Implications for Gut Microbiome Research</strong></span></h4><p>N-glycans represent a potential class of <strong>prebiotic substrates</strong> that can influence gut microbiota composition and activity.</p><p>Key findings suggest:</p><ul><li>Structural diversity of glycans affects <strong>microbial utilization patterns</strong></li><li>More complex glycans may promote <strong>greater microbiome diversity</strong></li><li>Specific glycan structures may selectively stimulate beneficial microbes</li></ul><p>This has led to growing interest in:</p><ul><li><strong>Synbiotic strategies</strong>, combining microbes with preferred substrates</li><li>Tailored dietary interventions to enhance <strong>metabolic outputs</strong>, such as short-chain fatty acids</li></ul><h4><span><strong>Methodological Considerations</strong></span></h4><p>A critical insight from this work is the importance of understanding <strong>analytical trade-offs</strong>:</p><ul><li>MALDI-TOF MS provides broader detection of glycan structures</li><li>LC-MS approaches offer greater reproducibility</li></ul><p>No single technique is universally optimal; instead, method selection should be guided by the specific research question.</p><h4><span><strong>Conclusion</strong></span></h4><p>N-glycans in dietary proteins represent a complex and biologically significant class of biomolecules with implications spanning nutrition, microbiology, and disease research. Advances in analytical methodologies continue to improve our ability to characterize these structures, despite challenges related to low abundance and structural diversity.</p><p>A deeper understanding of N-glycan composition and function may enable the development of targeted nutritional strategies and microbiome-based therapeutics, highlighting the growing importance of glycomics in modern life sciences.</p><blockquote><p><strong>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</strong></p></blockquote><blockquote><h4><strong>Concentrating on Chromatography Podcast</strong></h4><p>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!</p><p>You can find <strong>Concentrating on Chromatography Podcast </strong>in podcast apps:</p><ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL"><strong>Spotify</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185"><strong>Apple podcast</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography"><strong>podscan</strong></a></li></ul><p>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos"><strong>YouTube channel</strong></a></p></blockquote>

N‑Glycans, Whey Protein, and the Gut Microbiome: Mass Spec Insights with Matthew Bolino

<div><div><div><p><strong>Our immune system is incredibly powerful: among other things, it can recognize and destroy cancer cells. But tumors can be just as effective at avoiding detection – they build “invisibility shields” to protect themselves from attack.</strong></p></div></div><div><p>One breakthrough in cancer therapy has been immune checkpoint inhibitors (ICIs), drugs that reactivate immune T cells and help them fight tumors again. However, only about 20–50% of patients respond well to this treatment. Researchers are therefore seeking alternative therapeutic strategies. A small and well-known molecule called adenosine plays a key role in these efforts.</p><p>When tumor cells are stressed or dying, they release ATP, which is normally a signal that something is wrong in the tissue. But in the tumor microenvironment, ATP gets rapidly broken down by two enzymes, CD39 and CD73. Released adenosine acts like a chemical “calm-down” signal, binds to immune cells (T cells, NK cells, and others), and tells them to slow down, reducing their ability to kill cancer cells. Targeting CD73 therefore represents a promising strategy for developing new cancer treatments.</p></div><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/UOCHB_Nove_latky_mohou_podporit_imunitni_system_v_boji_s_rakovinou_88c5e82cd5.jpeg" alt="IOCB Prague: Development of potent inhibitors to boost the immune system's ability to fight cancer" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_UOCHB_Nove_latky_mohou_podporit_imunitni_system_v_boji_s_rakovinou_88c5e82cd5.jpeg 245w," sizes="100vw" width="661" height="363"></p><p>At IOCB Prague, interdisciplinary teams led by Jan Řezáč, Jan Konvalinka, and Michal Hocek used a newly developed high-throughput screening method to test over 5,000 compounds, identifying two ribonucleoside derivatives as promising CD73 inhibitors.</p><p>The scientists then improved the compounds’ activity by carefully modifying the ribonucleoside scaffold with bulky (het)aryl groups. Further optimization improved the pharmacokinetic properties of these compounds, yielding inhibitors with low clearance, long half-life, high solubility, and strong selectivity over related enzymes such as CD39.</p><p>In cellular experiments, the compounds reduced adenosine production in cancer cells, restored T cell activation, and showed no toxicity toward human fibroblasts. The most active compound showed a single-digit picomolar inhibition constant (Ki).</p><p>These findings establish a strong foundation for further in vivo efficacy and combination studies, which will explore the therapeutic potential of this novel inhibitor class.</p><blockquote><h4><strong>The Original article</strong></h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsptsci.5c00707"><strong>Potent Competitive Inhibitors of Ecto-5′-nucleotidase (CD73) based on 6-(Het)aryl-7-deazapurine Ribonucleoside 5′-O-Bisphosphonates</strong></a></h4><p>Ugnė Šinkevičiu̅tė, Magdalena Šímová, Radek Staník, Lenka Poštová Slavětínská, Kristýna Blažková, Pavel Šácha, Martin Lepšík, Jan Řezáč, Jan Konvalinka, Tereza Ormsby, Michal Tichý, Michal Hocek</p><p><i><span><strong>ACS Pharmacol. Transl. Sci.</strong></span></i><strong> </strong><span><strong>2026, 9, 1, 191–213</strong></span></p><p><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsptsci.5c00707">https://pubs.acs.org/doi/10.1021/acsptsci.5c00707</a></p><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/"><strong>CC-BY 4.0</strong></a></h6></blockquote><h4><strong>Abstract</strong></h4><p>CD73 generates immunosuppressive adenosine in the tumor microenvironment and is a promising target for cancer immunotherapy. We have designed and systematically studied diverse 2-substituted 7-deazapurine ribonucleoside 5′-<i>O</i>-bisphosphonates bearing a variety of (het)aryl groups at position 6 and discovered their highly potent and selective CD73 inhibition activity. The most active compounds (with single-digit picomolar <i>K</i><sub>i</sub>) contained bicyclic (het)aryl groups at position 6 in combination with chlorine at position 2. Further optimization of pharmacokinetic properties identified inhibitors with low clearance, long half-life, high solubility, and excellent selectivity over CD39 and NTPDase3. They effectively suppressed adenosine formation in MDA-MB-231 cells, rescued CD8<sup>+</sup> T cell activation, and were nontoxic to human fibroblasts. Overall, their profile compares favorably with <strong>AB680</strong>, a CD73 inhibitor currently in phase I/II clinical trials.</p></div>

Development of potent inhibitors to boost the immune system's ability to fight cancer

Article

Video

Scientists

Environment

Scientific article

Interview

Science and research

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) is a leading scientific institution in the Czech Republic, recognized internationally. Its primary mission is basic research in the fields of chemical biology and medicinal chemistry, organic and material oriented chemistry, chemistry of natural compounds, biochemistry and molecular biology, physical chemistry, theoretical chemistry, and analytical chemistry. 

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

The Analytical Scientist

Agilent Technologies

Technology Networks

Bruker

SelectScience

Shimadzu Corporation

<ul>
<li><p><strong>Discuss what GC-MS/MS is and what applicaitons it is used for (Dioxins, POPs, etc.)</strong></p>
</li>
<li><p><strong>Transition into an overview of APGC as a solution</strong></p>
</li>
<li><p><strong>Discuss challenges or limitations of the current GC/MS/MS technology</strong></p>
</li>
<li><p><strong>Share why using nitrogen as a carrier gas for GC/MS/MS analysis is optimal</strong></p>
</li>
</ul>
<p>Webinar Learning Objectives:</p>
<ul>
<li><p>Understanding GC-MS/MS and Its Applications:- Discuss the principles of gas chromatography-mass spectrometry (GC-MS/MS) and its role in analytical chemistry.- Explore specific applications of GC-MS/MS, including its use in detecting dioxins, persistent organic pollutants (POPs), and other environmental contaminants.</p>
</li>
<li><p>Introduction to APGC (Atmospheric Pressure Gas Chromatography):-. Provide an overview of Atmospheric Pressure Gas Chromatography (APGC) as an alternative solution to traditional GC-MS/MS.- Highlight the advantages and unique features of APGC, such as improved sensitivity, reduced matrix effects, and enhanced selectivity.</p>
</li>
<li><p>Challenges and Innovations in GC-MS/MS Technology:- Identify the current challenges and limitations faced by GC-MS/MS technology.- Discuss recent innovations and advancements aimed at overcoming these challenges.- Emphasize the importance of using nitrogen as a carrier gas for GC-MS/MS analysis, considering its inertness, availability, and compatibility with various detectors.</p>
</li>
</ul>
<blockquote>
<p><strong>Prtesenter:</strong> Frank Dorman (Senior Principal Market Development Mgr, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Frank Dorman is currently Senior Principal Market Development Manager for Waters focusing on their global environmental business and, concurrently, a Resident Scholar in the Chemistry Department at Dartmouth College in Hanover, NH where he is active in teaching analytical chemistry to undergraduates and graduate students.</p>
</blockquote>
<blockquote>
<p>In his role at Waters, Frank manages the research-focused environmental market, external collaborations, and interfaces with R&amp;D for new product development. Prior to this, Frank was an Associate Professor in the Department of Biochemistry and Molecular Biology (BMB) sat Penn State University in University Park, PA. At Penn State, Frank served as a member of the Graduate Faculty in: Biochemistry, Microbiology and Molecular Biology (BMMB), Chemistry (CHEM), Biogeochemistry (BGC) and the Forensic Science Program (FRNSC) and the Center for Molecular Toxicology and Carcinogenesis. Franks scientific interests are in gas and liquid chromatography and fundamental characterization, instrumentation and column development, as well as mass spectrometry and atomic spectroscopy as applied to trace analysis in complex sample matrices.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Sarah Dowd (Principal Mass Spectrometry Applications Specialist, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Sarah Dowd joined Waters as a mass spectrometry application specialist in 2015 after earning her PhD in analytical chemistry from the University of Illinois at Urbana Champaign.</p>
</blockquote>
<blockquote>
<p>In her eight years at Waters in the Americas application lab, Sarah has collaborated with many customers looking to expand the MS capabilities of their laboratories with Water&#39;s instruments and software. Specializing in analyses in food, environmental, and polymeric materials characterization, she has done extensive work looking at environmental contaminants with tandem quadrupole and high resolution mass spectrometers.</p>
</blockquote>
<blockquote>
<p>One of the hot topics for the past couple of years is the analysis of per- and polyfluoroalkyl substances (PFAS) and Sarah has collaborated with customers and other scientists within Waters to guide the next phase of PFAS testing with Waters mass spectrometry systems.</p>
</blockquote>


Waters Corporation: APGC Roundtable: Unveiling the Pathways of GC-MS/MS Evolution

APGC Roundtable: Unveiling the Pathways of GC-MS/MS Evolution

Discuss what GC-MS/MS is and what applicaitons it is used for (Dioxins, POPs, etc.)

APGC Roundtable: Unveiling the Pathways of GC-MS/MS Evo

<p><strong>Join us for an insightful webinar where we will explore the critical aspects of differentiating good from bad data and how this distinction can significantly influence your results. From screening to quantification, discover the value of targeted data analysis workflows using non-targeted data with our innovative software and hardware.</strong></p><p>Find by Formula algorithm. Learn to identify the most suitable MS/MS approach for your experiments, initiate quantitation for your compounds of interest, and incorporate retention times (RTs) and MS/MS spectra into a custom database and library.</p><p>This session is designed to enhance your understanding and application of Q-TOF data analysis, ensuring robust and reliable outcomes.</p><blockquote><p><strong>Presenter:</strong> Hannah Florance (Agilent Technologies)</p><p>Hannah has had multiple roles in the life sciences, starting as a protein chemist, before moving into proteomics and then metabolomics. A major part of her time working in academia involved running LC and GCMS core facilities supporting projects ranging from synthetic biology to cancer research. She is currently an LCMS applications specialist for Agilent.<br><br><strong>Presenter:</strong> Stefan Schaebler (Application Specialist LC/MS, Agilent Technologies)</p><p>Stefan completed his PhD in Biology, specializing in LC-MS-based lipidomics and metabolomics. Following his doctoral studies, he joined Agilent Technologies as an LC/MS Application Specialist. In this role, Stefan focuses on small molecule applications using LC-QTOF, with a strong emphasis on software tools and data interpretation.</p></blockquote>

Agilent Technologies: MassHunter Masterclass Months

MassHunter Qual – The Solid Pillar in Q-TOF Data Analysis

We will explore the critical aspects of differentiating good from bad data and how this distinction can significantly influence your results.

<div><p><strong>To unravel the functions of the vast universe of small molecules in human biology it is essential to first detect and quantify these molecules—a task carried out by the field of metabolomics. In traditional liquid chromatography-mass spectrometry (LC-MS)-based metabolomics, quantitative analysis is divided across two categories: relative or absolute.&nbsp;&nbsp;&nbsp;</strong></p><p>In this webinar we will explore the importance of metabolomics in disease research, and the challenges associated with LC-MS based metabolomics studies. We will also introduce Pyxis, a scalable, machine learning-based approach to absolute quantitation of metabolites across various matrices, and potential applications in research and the clinic.&nbsp;</p><p><strong>Learning Objectives</strong></p><ul><li><strong>The application of quantitation in understanding metabolite functions in biological systems.</strong></li><li><strong>The experimental requirements of absolute and relative quantitation of metabolites along with their benefits and limitations.</strong></li><li><strong>Introduction of Pyxis, a method that enables scalable absolute quantitation of metabolites without relying on isotopically labeled standards.</strong></li></ul><blockquote><p><strong>Presenter:</strong> Naama Kanarek, PhD (Assistant Professor, Pathology Department at Boston Children’s Hospital and Harvard Medical School)</p><p>A native of Jerusalem, Israel, Dr. Naama Kanarek trained at the Hebrew University, where she earned a BSc in medical science, an MSc in proteomics and microbiology, and a PhD in immunology and cancer research (including one year at Columbia University Medical Center, NY). Dr. Kanarek’s postdoctoral research was performed under the supervision of Prof. David M. Sabatini at MIT’s Whitehead Institute.</p><p>Dr. Kanarek is the recipient of a number of awards and honors, including the Margaret and Herman Sokol Postdoctoral Award, the Leukemia and Lymphoma Society New Idea Award, the Hebrew University Women in Science Postdoctoral Award, the Weizmann Institute Postdoctoral Award for Advancing Women in Science and a Revson Fellow of that program, and the James Sivarsten Prize in Pediatric Cancer Research. Her postdoctoral work was supported by fellowships from the American Association for Cancer Research and the European Molecular Biology Organization.</p><p>Dr. Kanarek’s laboratory is interested in folate metabolism, and the metabolic adaptations of cells as they move around and migrate to new sites. They apply genetic perturbations, biochemical assays, molecular biology, functional genomic screens, and metabolite profiling by mass spectrometry in cell-culture systems and in vivo. They study basic folate biology including folate metabolism, folate-related signal transduction, the oncogenic role of folate and folate homeostasis in normal physiology and pathological conditions.</p><p><strong>Presenter:</strong> Jennifer M. Campbell, PhD (Chief Scientific Officer, Matterworks, Inc.)</p><p>Jennifer M. Campbell, PhD is currently Chief Scientific Officer at Matterworks, a multidisciplinary startup focused on using the power of deep learning on raw mass spectrometric data. Their first product, Pyxis, enables scalable quantitative metabolomics through the use of AI. Prior to Matterworks, Dr. Campbell worked at Novartis Institutes of Biomedical Research, heading up MS and separations within the Cambridge (MA) chemistry department. Dr. Campbell served as technical lead of NeoBase2, an FDA 510K approved assay for newborn screening at Perkin Elmer and Director of Proteomics at BG Medicine. Her career started in instrument development - she obtained her PhD, which focused on the development of a linear ion trap-TOFMS at the University of British Columbia under Don Douglas and she worked for eight years at Applied Biosystems, aiding in the development of all aspects of the MALDI TOF/TOF product line (4700, 4800, and 5800). She has authored numerous papers, patents, and book chapters.</p></blockquote></div>

The Analytical Scientist: A scalable approach to absolute quantitation in metabolomics

A scalable approach to absolute quantitation in metabolomics

We will explore the importance of metabolomics in disease research, and the challenges associated with LC-MS based metabolomics studies.

<div><div id="inner_content_body_text" data-content-id="391110"><p><strong>Per- and polyfluoroalkyl substances (PFAS) are synthetic chemicals prevalent across numerous industries and used in many everyday products, but their persistent and bioaccumulative nature raises critical health and environmental concerns. Join us for our upcoming Ask Me Anything (AMA) Q&amp;A session, where you can explore the latest research, regulatory challenges and advancements in the field.</strong></p><p>During this hour-long virtual session, you’ll have the unique opportunity to ask your most pressing questions directly to our expert speaker, Dr. Ian Ross, in real time.</p><h4><strong>About Our Expert</strong></h4><p>We are honored to host Dr. Ian Ross, Global PFAS Practice Lead at CDM Smith and visiting professor at Manchester Metropolitan University. Dr. Ross is a distinguished biochemist specializing in contaminated land assessment and PFAS decontamination. His extensive expertise is reflected in over 100 publications, including a comprehensive 204-page chapter on PFAS in the Emerging Contaminants Handbook.</p><h4><strong>What to Expect</strong></h4><p>Ian will connect with our live audience to address a broad spectrum of topics related to PFAS. While the spontaneous nature of an AMA session makes it impossible to predict every question, we anticipate discussions will focus on:</p><ul><li><strong>PFAS contamination:</strong> Latest research and case studies</li><li><strong>Environmental and health impacts:</strong> Emerging evidence and implications</li><li><strong>Regulatory challenges: </strong>Current frameworks and future directions</li><li><strong>Applications and concerns:</strong> Industrial uses and associated risks</li></ul><div><div><h4><strong>Why Attend?</strong></h4></div></div><ul><li><strong>Expert insights:</strong> Gain knowledge directly from a leading authority in PFAS.</li><li><strong>Live interaction:</strong> Have your questions addressed in real time for personalized answers.</li><li><strong>Exclusive content:</strong> Access in-depth discussions that you won't find anywhere else.</li></ul><p><strong>Space is limited! Register now to secure your spot for this exclusive AMA session.</strong></p><p><span><strong>Presenter:</strong> Ian Ross, PhD </span>(CDM Smith / Global PFAS Practice Lead, Manchester Metropolitan University)</p></div></div>

Technology Networks: Ask Me Anything: PFAS

Ask Me Anything: PFAS

Ian will connect with our live audience to address a broad spectrum of topics related to PFAS.

<p><strong>Hear about the latest advancements in translational proteomics and metabolomics. From the molecular mechanisms of disease pathology to the latest technological developments in diagnostics and treatment.</strong></p><h5><strong>Key Learning Objectives:</strong></h5><ul><li>Spatial proteomics to assess health and diseases</li><li>Absolute quantitation of human proteins</li><li>The latest innovations in proteomics and metabolomics instrumentation and data analysis</li><li>Biomarker-guided precision medicine</li></ul><h4><strong>Day 1 – October 30</strong></h4><h5><strong>15:00 – 15:50 GMT: The Human Protein Atlas – Creating a Pan-Disease Resource Based on Next Generation Blood Profiling</strong></h5><ul><li>Mathias Uhlén, PhD (KTH Royal Institute of Technology)</li></ul><h5><strong>15:50 – 15:55 GMT:</strong> Networking Break</h5><h5><strong>15:55 – 16:15GMT: Mitigating Sorter-Induced Cellular Stress with Cartridge, Microfuildics-Based Sorting</strong></h5><ul><li>Crystal Montoya (Miltenyi Biotec)</li></ul><h5><strong>16:15 – 16:20 GMT:</strong> Networking Break</h5><h5><strong>16:20 – 16:40 GMT: Speaker to be announced</strong></h5><h5><strong>16:40 – 16:45 GMT</strong>: Networking Break</h5><h5><strong>16:45 – 17:35 GMT: Spatial Tissue Proteomics to Assess Health and Disease</strong></h5><ul><li>Fabian Coscia, PhD (Max Delbrück Center)</li></ul><h5><strong>17:35 – 17:40 GMT:</strong> Networking Break</h5><h5><strong>17:40 – 18:00 GMT: The Sulpho-Phospho-Vanillin Assay: Accurate Lipid Normalization in Quantitative Lipidomics</strong></h5><ul><li>Karri Basso, PhD (University of Florida)</li></ul><h5><strong>18:00 – 18:05 GMT:</strong> Networking Break</h5><h5><strong>18:05 – 18:55 GMT: Proteomics for Cancer Precision Medicine</strong></h5><ul><li>Janne Lehtiö, PhD (Karolinska Instutet)</li></ul><h5><strong>18:55 – 19:00 GMT: </strong>Networking Break</h5><h5><strong>19:00 – 19:20 GMT: How Breakthroughs in Depth, Scale and Speed are Unlocking New Proteomic Discovery</strong></h5><ul><li>Aaron Gajadhar, PhD (Seer Bio)</li></ul><h5><strong>19:20 – 19:25 GMT: </strong>Networking Break</h5><h5><strong>19:25 – 19:55 GMT:</strong> Phantom Metabolites: Unraveling Metabolic Shadows</h5><ul><li>Gary Siuzdak, PhD (Scripps Research Institute)</li></ul><h5><strong>19:55 GMT:</strong> End of Day 1</h5><div><div><div><h5><strong>Who Should Attend:</strong></h5><ul><li>Scientists and researchers seeking to expand their knowledge</li><li>Pharmaceutical and biotech professionals driving drug development</li><li>Clinicians looking to improve patient care</li><li>Academicians exploring new research avenues</li><li>Graduate students and postdoctoral fellows building their careers</li></ul><blockquote><p><strong>Presenter: </strong>Mathias Uhlén, PhD (Professor, KTH - Royal Institute of Technology)</p><p><strong>Presenter:&nbsp;</strong>Christoph Borchers, PhD (Professor, McGill University)</p><p><strong>Presenter:</strong>&nbsp;Janne Lehtiö, PhD (Professor, Karolinska Institutet)</p><p><strong>Presenter:</strong>&nbsp;Crystal Montoya (Senior Marketing Product Manager, Miltenyi Biotec)</p><p><strong>Presenter:</strong>&nbsp;Kari Basso, PhD (Director of Mass Spectrometry Research and Education, University of Florida)</p><p><strong>Presenter:&nbsp;</strong>Fabian Coscia, PhD (Group Leader, Max Delbrück Center)</p><p><strong>Presenter:</strong>&nbsp;Simone Sidoli, PhD (Assistant Professor, Albert Einstein College of Medicine)</p><p><strong>Presenter:</strong>&nbsp;Hagen Magnus Gegner, PhD (Content and Digital Marketing, CTC Analytics)</p><p><strong>Presenter:</strong>&nbsp;Matt Willetts, PhD (Proteomics Applications Manager, Bruker Daltonics)</p><p><strong>Presenter:&nbsp;</strong>Matteo Tardelli, PhD (Senior Biomarker Scientist, Owlstone Medical)</p><p><strong>Presenter:&nbsp;</strong>Aaron Gajadhar, PhD (Director, Strategic Applications, Seer)</p><p><strong>Presenter:&nbsp;</strong>Gary Siuzdak, PhD (Professor and Senior Director, Scripps Research Institute)</p></blockquote></div></div></div>

Technology Networks: Advances in Proteomics & Metabolomics 2024

Advances in Proteomics & Metabolomics 2024 (Day 1)

Hear about the latest advancements in translational proteomics and metabolomics. 

Advances in Proteomics & Metabolomics 2024  (Day 1)

<p><strong>Hear about the latest advancements in translational proteomics and metabolomics. From the molecular mechanisms of disease pathology to the latest technological developments in diagnostics and treatment.</strong></p><h5><strong>Key Learning Objectives:</strong></h5><ul><li>Spatial proteomics to assess health and diseases</li><li>Absolute quantitation of human proteins</li><li>The latest innovations in proteomics and metabolomics instrumentation and data analysis</li><li>Biomarker-guided precision medicine</li></ul><h4><strong>Day 2 – October 31</strong></h4><h5><strong>15:00 – 15:50 GMT: A Novel Strategy for the Absolute Quantification of Human Proteins</strong></h5><ul><li>Christoph Borchers, PhD (McGill University)</li></ul><h5><strong>15:50 – 15:55 GMT: </strong>Networking Break</h5><h5><strong>15:55 – 16:15 GMT: From Single Cells to the Metaproteome: Latest Developments in timsTOF Technology for Proteomics</strong></h5><ul><li>Matt Willetts, PhD (Bruker)</li></ul><h5><strong>16:15 – 16:20 GMT: </strong>Networking Break</h5><h5><strong>16:20 – 17:10 GMT: Single-Cell Chromatin Proteomics to Investigate the Biology of Exceptional Longevity</strong></h5><ul><li>Simone Sidoli, PhD (Albert Einstein College of Medicine)</li></ul><h5><strong>17:10 – 17:15 GMT: </strong>Networking Break</h5><h5><strong>17:15 – 17:35 GMT: Optimizing Metabolomics Workflows: From Sample Preparation to Multi-omics Integration</strong></h5><ul><li>Hagen Magnus Gegner, PhD (CTC Analytics)</li></ul><h5><strong>17:35 – 17:40 GMT:</strong> Networking Break</h5><h5><strong>17:40 – 18:10 GMT: Analyzing Metabolic Responses to a Standardized Meal Challenge Using Exhaled Breath</strong></h5><ul><li>Matteo Tardelli, PhD (Owlstone Medical)</li></ul><h5><strong>18:10 GMT: </strong>Event Close</h5><h5><strong>Who Should Attend:</strong></h5><ul><li>Scientists and researchers seeking to expand their knowledge</li><li>Pharmaceutical and biotech professionals driving drug development</li><li>Clinicians looking to improve patient care</li><li>Academicians exploring new research avenues</li><li>Graduate students and postdoctoral fellows building their careers</li></ul><blockquote><p><strong>Presenter: </strong>Mathias Uhlén, PhD (Professor, KTH - Royal Institute of Technology)</p><p><strong>Presenter:&nbsp;</strong>Christoph Borchers, PhD (Professor, McGill University)</p><p><strong>Presenter:</strong>&nbsp;Janne Lehtiö, PhD (Professor, Karolinska Institutet)</p><p><strong>Presenter:</strong>&nbsp;Crystal Montoya (Senior Marketing Product Manager, Miltenyi Biotec)</p><p><strong>Presenter:</strong>&nbsp;Kari Basso, PhD (Director of Mass Spectrometry Research and Education, University of Florida)</p><p><strong>Presenter:&nbsp;</strong>Fabian Coscia, PhD (Group Leader, Max Delbrück Center)</p><p><strong>Presenter:</strong>&nbsp;Simone Sidoli, PhD (Assistant Professor, Albert Einstein College of Medicine)</p><p><strong>Presenter:</strong>&nbsp;Hagen Magnus Gegner, PhD (Content and Digital Marketing, CTC Analytics)</p><p><strong>Presenter:</strong>&nbsp;Matt Willetts, PhD (Proteomics Applications Manager, Bruker Daltonics)</p><p><strong>Presenter:&nbsp;</strong>Matteo Tardelli, PhD (Senior Biomarker Scientist, Owlstone Medical)</p><p><strong>Presenter:&nbsp;</strong>Aaron Gajadhar, PhD (Director, Strategic Applications, Seer)</p><p><strong>Presenter:&nbsp;</strong>Gary Siuzdak, PhD (Professor and Senior Director, Scripps Research Institute)</p></blockquote>

Advances in Proteomics & Metabolomics 2024 (Day 2)

<div><div><div><p><strong>Targeted protein degradation (TPD) is a powerful therapeutic modality to eliminate disease-causing proteins that are resistant to conventional drugs. In this webinar, we present a high-throughput scalable proteomics approach that utilizes label-free, single-shot dia-PASEF<sup>®</sup> mass spectrometry to identify novel degrader targets on a large scale with unmatched coverage, accuracy, and speed. A combination of DIA-NN software and advanced statistical tools guarantees rapid, automated analysis of large proteomics datasets with highest precision of quantification, data completeness and sensitivity. A slice-PASEF-based global ubiquitinomics approach will be presented that verifies degrader-induced modifications with an unprecedented depth of 50,000 ubiquitination sites. In addition, a data analysis suite designed for user-friendly evaluation and in-depth meta-analysis will be shown, making proteomics data easily accessible for target identification, SAR optimization, library expansion and strategic drug discovery decisions.</strong></p></div></div></div><div><div><div><p><strong>About NEOsphere Biotechnologies:</strong></p><p>NEOsphere Biotechnologies is a leading partner in TPD (Targeted Protein Degradation) proteomics, collaborating with pharmaceutical and biotechnology companies to advance drug discovery and develop innovative degrader pipelines. The platform combines cutting-edge mass spectrometry technologies with advanced biostatistical data analysis, enabling high-throughput proteomic screening of entire degrader libraries and mechanistic target validation, including global ubiquitinomics. NEOsphere Biotechnologies offers unmatched sensitivity, precision, and turnaround times, facilitating the large-scale identification of novel degrader targets and the systematic exploration of previously undruggable therapeutic targets.<br><br><strong>You will learn about:&nbsp;</strong></p><ul><li>A high-throughput proteomics approach that utilizes label-free, single-shot dia-PASEF to identify novel degrader targets on a large scale with unmatched coverage, accuracy, and speed</li><li>The verification of degrader-induced modifications using an optimized acquisition strategy based on slice-PASEF-based global ubiquitinomics</li><li>The benefit of combining the capabilities of a timsTOF HT and a timsTOF Ultra 2</li></ul><blockquote><p><strong>Presenter: </strong>Uli Ohmayer, Ph.D. (Head of Mass Spectrometry and Founder, NEOsphere Biotechnologies GmbH, Munich, Germany)</p></blockquote></div></div></div>

Bruker: Unlock the therapeutic potential of targeted protein degradation with deep proteomic screening

Unlock the therapeutic potential of targeted protein degradation with deep proteomic screening

High-throughput scalable proteomics approach that utilizes label-free, single-shot dia-PASEF® mass spectrometry

Targeted protein degradation with deep proteomic screening

<p><strong>The complexity of biological systems and diseases, such as Alzheimer’s disease, necessitates spatial multiomics techniques to gain a holistic understanding of cell-cell interactions and communication. A singular approach to spatial multiomics is possible with MALDI Imaging, including label-free imaging of small molecules, lipids, drugs, and glycans. Additionally, with technology developed by AmberGen, Inc., photocleavable mass-tag (PCMT) conjugated affinity probes are available for antibodies, oligos, and lectins.</strong></p><p><strong>Key Learning Objectives:</strong></p><ul><li>Learn the spatial biology utility of MALDI Imaging</li><li>Understand multiomics workflows and the applications to disease-based research</li></ul><p><strong>Who Should Attend:</strong></p><ul><li>Researchers interested in multiomics brain analysis</li><li>Investigators researching Alzheimer’s disease</li></ul><blockquote><p><strong>Presenter: </strong>Mark Lim, Ph.D. (Chief Scientific Officer and Executive VP, AmberGen Inc., Billerica, MA, USA)</p><p>Mark Lim Ph.D. is the Chief Scientific Officer and Executive VP at AmberGen Inc. He has over 23 years’ experience in the biotechnology industry and has been awarded over 20 patents which underlie key technologies in the biotechnology industry, including in the fields of proteomics, genomics/transcriptomics, and diagnostics. His early work at AmberGen on photocleavable linkers and protein engineering contributed to the commercialization of a variety of novel reagents including PC-Biotin, PC-Phosphoramidites and fluorescent suppressor tRNAs. Dr. Lim now leads the application of these core AmberGen technologies to multiomic biomarker discovery and biomarker-driven diagnostics.</p><p><strong>Presenter:</strong> Kate Stumpo, Ph.D. (Senior Market Manager, Bruker Scientific, Billerica, MA, USA)</p><p>Dr. Kate Stumpo is a Market Manager which entails messaging and marketing for MALDI Imaging. Dr. Stumpo completed her Ph.D. at Texas A&amp;M University, and is an expert in MALDI applications, including MALDI Imaging.</p></blockquote>

Bruker: Advancing understanding of Alzheimer’s disease using multiomics spatial biology

Advancing understanding of Alzheimer’s disease using multiomics spatial biology

Learn the spatial biology utility of MALDI Imaging. Understand multiomics workflows and the applications to disease-based research.

Understanding of Alzheimer’s with multiomics spatial biology

<p><strong>In today’s fast-paced research environment, optimizing lab workflows is crucial to maintaining productivity and ensuring high-quality results. Sample preparation is a critical step in chromatography and mass spectrometry, yet it often involves time-consuming and error-prone manual processes.</strong></p><p>Join us for an exclusive webinar with Dr. Jens Lättig, Senior Scientist at Tecan and Dr. Cassandra Rusher, European Technical Support Specialist at Eprep, where they’ll reveal how the Resolvex® Prep revolutionizes sample preparation for chromatography and mass spectrometry.</p><p><strong>Key learning objectives:</strong></p><ul><li>Slash prep time: Discover how you can reduce your setup to just 5–15 minutes, freeing you to focus on critical tasks while Resolvex® Prep works autonomously.</li><li>Enhance accuracy: Learn how analytical syringes and specialized tools deliver consistent, reliable results – minimizing human error.</li><li>Achieve consistency: Find out how you can achieve repeatable results across various sample types and workflows, streamlining your processes.</li><li>Unlock versatility: Explore Resolvex® Prep’s built-in wash station, RFID deck scan, and seamless sample transfer, all designed to meet your research needs.</li></ul><p><strong>Who should attend?</strong></p><ul><li>Laboratory scientists and managers from analytical laboratories in: pharma, biopharma, biotech, the food industry, the environmental sector, agriculture, drug screening, proteomics, and metabolomics.</li></ul><p><strong>Certificate of attendance</strong></p><p>All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.</p><blockquote><p><strong>Presenter:</strong> Jens Lattig, PhD (Sales Development Manager Proteomics &amp; MS Sample Prep, Tecan)</p><p>Dr. Jens Lättig is a Sales Development Manager Proteomics &amp; MS Sample Preparation at Tecan. He has a PhD in biochemistry, and has worked in drug research projects in Germany and France. At Tecan, he is responsible for the Resolvex™ instruments and consumables portfolio in Europe.</p><p><strong>Presenter: </strong>Cassandra Rusher, PhD (European Technical Support Specialist, Eprep)</p><p>Dr. Cassandra Rusher is a technical support specialist for the Resolvex Prep. at Eprep. She has a PhD in chemistry and a background specializing in chromatography including sample preparation. Her previous roles have included technical support and product management in the analytical chromatography sector. Her focus now is on supporting the automation of sample preparation methods across a range of industries that are utilizing analytical chromatography techniques.</p><p><strong>Moderator:</strong> Carrie Haslam (Associate Editor, SelectScience)</p></blockquote>

SelectScience: Efficient sample prep for expert mass spectrometry and chromatography

Efficient sample prep for expert mass spectrometry and chromatography

Join us for a webinar where we will reveal how the Resolvex® Prep revolutionizes sample preparation for chromatography and mass spectrometry.

Efficient sample prep for MS and chromatography

<p><strong>Are you ready to transform your pharmaceutical operations? Don’t miss our exclusive session on Shimadzu Digital Classrooms and begin your journey towards Pharma digital transformation (DX). Discover how Shimadzu’s pioneering AI technologies and digital solutions are ushering in a new era of pharma innovation.</strong></p><p>In this informative session, explore how Shimadzu is reshaping the drug development landscape. Learn how our innovative tools effectively streamline workflows, enhance lab efficiency, and maintain strict compliance with regulatory standards.</p><p>Whether you’re a forward-thinking researcher, a quality assurance professional, or a strategic decision-maker, this session is your gateway to mastering AI and digital transformation. Equip yourself with the expertise and resources to stay ahead in the industry.</p><p>This is an opportunity not to be missed – Register Now!</p><p><strong>Learning Objectives:&nbsp;</strong></p><ul><li>Understand how to stay conforming to the Pharma regulations and USP 621 changes with Shimadzu Living Laboratory</li><li>Explore Shimadzu AI and Automation to elevate your lab workflows effectively</li><li>Learn about the AI features of Shimadzu Ai-series and Nexera series</li><li>Gain insights into efficient quality control strategies with Shimadzu Data Management and Software</li></ul><blockquote><p><strong>Presenter: </strong>Liw Wan Tung (Assistant Market Manager (Pharma) Shimadzu (Asia Pacific) Pte Ltd)</p><p>Wan Tung is the LC Product Manager and Pharmaceutical market in-charge at Shimadzu Asia Pacific Pte Ltd. She is the LC expert with more than 15 years of working experience in analytical science, specializing in method development of various LC and LCMS applications. In 2012, she joined Shimadzu to develop end-to-end workflow solutions for the customers. She has supported a multitude of applications from impurity analysis to drug discovery and biopharmaceutical applications. Prior to joining Shimadzu, Wan Tung started her professional career as a QAQC chemist in Pharmaceutical multinational company. Wan Tung earned her bachelor’s honour's degree in chemistry back in 2009.</p><p><strong>Presenter:</strong> Kanimozhi Sivarajan (Informatics Manager Shimadzu (Asia Pacific) Pte Ltd)</p><p>Dr. Kani is having 10 years of experince in Laboratory Management and Informatics &nbsp;Systems. She is serving as Informatics Manager at Shimadzu Asia Pacific, Singapore, &nbsp;providing Lab Informatics Solutions such as LabSolutions CS, LIMS and other QMS applications. She is supporting customers from various segments on implementing laboratory automation and responsible for providing consultation on streamlining Lab Workflows, Regulatory Compliance requirements for Electronic Data Management and Lab Practices/Analysis.&nbsp;</p></blockquote>

Shimadzu:  Realizing Pharma DX: Discover Shimadzu’s AI-Driven Solutions And Automation

 Realizing Pharma DX: Discover Shimadzu’s AI-Driven Solutions And Automation

Discover how Shimadzu’s pioneering AI technologies and digital solutions are ushering in a new era of pharma innovation.

LCMS webinars focusing on LC/MS - page 44